Lung Cancer
Lung Cancer Content
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORY
Sign me up!
Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Helena Yu
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Dr Helena Yu is an associate attending and the research director of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) in New York, NY, USA. read more
In addition to her role as a practising medical oncologist, Dr Yu is a clinical and translational researcher with a focus on improving the survival of patients with EGFR-mutant lung cancers. She oversees the research programme for EGFR-mutant lung cancers at MSK, which includes developing effective new therapies for lung cancer, identifying biomarkers for targeted treatments, lineage plasticity and adaptive mutagenesis as pathways of resistance to targeted therapy, and establishing risk-adaptive treatment strategies that tailor treatment to patients based on risk. Dr Yu has established several mechanisms of resistance to first- and third-generation EGFR tyrosine kinase inhibitors and reported on the prognostic significance of concurrent alterations in EGFR-mutant lung cancer seen on next-generation sequencing.Â
Dr Yu has been the principal investigator of 30 clinical trials, including 10 investigator-initiated trials, focused on EGFR-mutant lung cancer.
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Dr Antonio Passaro
European Institute of Oncology, Milan, Italy
Dr Antonio Passaro is a medical oncologist and currently holds the position of senior staff physician at the Division of Thoracic Oncology, European Institute of Oncology in Milan, Italy. read more
Dr Passaro is a global authority and leader in lung cancer research and clinical practice. His main areas of research and clinical interest are predictive biomarkers, in particular EGFR and related targeted and immunotherapy agents, from discovery to validation in the clinical setting. He is also highly involved in the use of targeted agents in non-metastatic settings, either alone, or in a multimodality approach, for early or locally-advanced disease.Â
Dr Passaro is involved in a portfolio of many clinical trials, both industry-funded and academic, investigating a range of novel lung cancer therapies. He has published more than 120 articles in peer-reviewed journals. He also serves as a member of several national and international scientific committees. Notably, he has authored guidelines for ESMO (European Medical Society for Medical Oncology) and AIOM (Italian Association of Medical Oncology), guiding the management and treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Dr Antonio Passaro discloses: Consultancy fees from Bayer and Johnson & Johnson (Janssen Pharmaceuticals). Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GSK, Johnson & Johnson (Janssen Pharmaceuticals), Merck Sharp and Dohme, MundiPharma, Novartis, Pfizer and Roche.
Dr Aaron Lisberg
University of California, Los Angeles (UCLA), Los Angeles, CA, USA
Dr Aaron Lisberg is a thoracic medical oncologist at the University of California, Los Angeles (UCLA), USA. read more
Dr Lisberg specializes in novel drug development, antibody–drug conjugates (ADCs), immunotherapy and metabolically-targeted therapies in patients with advanced malignancies, with a focus on lung cancer. He is board-certified in haematology and medical oncology.
Dr Lisberg conducts translational research on novel therapeutic approaches in advanced malignancies and has a wide range of ongoing research projects, including the evaluation of factors predictive of response or toxicity to ADCs and immune checkpoint inhibitors, pre-clinical/clinical evaluation of novel metabolic therapies, and assessment of effective treatments in patients with targetable tumour alterations. He is also the clinical principal investigator and sub-investigator of several clinical trials evaluating novel therapeutics in various malignancies, including phase I, II and III assessments.
Dr Aaron Lisberg discloses: Advisory board or panel speaker fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron and Sanofi group of companies. Consultancy fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron and Sanofi group of companies. Grants/research support from AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics and WindMIL Therapeutics, Inc.
Dr Sara Pilotto
University of Verona, Verona, Italy
Dr Sara Pilotto is a medical oncologist and associate professor at the University of Verona in Verona, Italy. read more
Dr Pilotto completed her graduate studies and residency in medical oncology at the University of Verona and trained in the Translational Research Unit at the Pangaea Biotech laboratory, Quiron-Dexeus University Hospital in Barcelona, Spain. In 2019, she completed her PhD in Inflammation, Immunity and Cancer at the University of Verona in Italy.
Dr Pilotto leads the clinical and research team dedicated to thoracic malignancies at the University of Verona, as well as the FORCE (Focus on Research and Care) team, an integrated group dedicated to a comprehensive approach to patients with cancer (with a specific focus on nutrition and physical activity).
Dr Pilotto is a member of the Lung Cancer Guidelines Experts Panel of a Italian Association of Medical Oncology (AIOM) and a member of the European Society of Medical Oncology (ESMO) Leadership Program 2019.
Dr Sara Pilotto discloses: Advisory board/panel speaker fees from Amgen, AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Takeda. Consultancy fees from Boehringer Ingelheim. Speaker’s bureau fees from Amgen, AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Takeda.
Ms Jackie Fenemore
The Christie NHS Foundation Trust, Manchester, UK
Jackie Fenemore is a lung cancer nurse clinician working with the Lung Medical Oncology and Clinical Oncology Team at the Christie Hospital Foundation Trust, in Manchester, UK. read more
After qualifying as a registered nurse in 1995, she has worked at The Christie Hospital for over 29 years. From 2007 to 2017, she served as a lung cancer nurse specialist. Following the completion of her MSc in advanced practice in 2017, she transitioned to the role of lung cancer nurse clinician at the advanced nursing practitioner level.
Jackie became a qualified non-medical prescriber in 2009 and regularly manages patients in treatment and follow-up, prescribing both systemic and oral therapies, along with supportive medications, in medical and nurse-led oncology clinics. She also leads a team of four lung clinical nurse specialists and has worked closely with Macmillan to expand their nursing services.
Jackie was a member of the Lung Cancer Nurses UK committee from 2012 to 2022, serving as chair from 2019 to 2022, during which time she developed the Lung Cancer Nurses Professional Development Framework. She has also been part of the British Thoracic Oncology Group (BTOG) steering committee and Lung Cancer Europe (LuCE). Currently, she is a steering group member of the Global Lung Cancer Coalition (GLCC) Committee.
Jackie presented at WLCC in 2021 and 2022 on patient advocacy work with the GLCC.
Ms Jackie Fenemore discloses: Advisory board/panel fees from Roche (relationship terminated).
Prof. Dr Egbert F Smit
Netherlands Cancer Institute, Amsterdam, Netherlands and Leiden University Medical Center, Leiden, Netherlands
Prof. Dr Egbert Smit is a professor of pulmonary medicine, specializing in pulmonary oncology, at both the Department of Thoracic Oncology at the Netherlands Cancer Institute and Leiden University Medical Center in Leiden, Netherlands. read more
Prof. Smit graduated from the University of Groningen, The Netherlands, in 1988 and earned his PhD in 1991 with a thesis titled ‘Aspects of Chemotherapy for Lung Cancer’. After completing his specialist training in pulmonary medicine, he held various positions in both academic and general hospital settings. In his current roles, Prof. Smit leads preclinical and translational research focused on all aspects of lung cancer, ranging from carcinogenesis to the treatment of metastatic disease.
Prof. Smit has authored over 500 peer-reviewed papers and 30 book chapters, and regularly serves as a reviewer for leading oncology journals.
Prof. Egbert Smit discloses: Advisory board or panel fees from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen Pharmaceuticals, Merck Serono, MSD, Pfizer and Takeda. Consultancy fees from Eli Lilly. Grants/research support from AstraZeneca, BMS and Merck.
